Beyond the renin–angiotensin–aldosterone system (RAAS) blockers, recent evidence from clinical trials established sodium-glucose cotransporter 2 inhibitors (SGLT2i), non-steroidal mineralocorticoid receptor antagonists (NS-MRA) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) as effective add-on therapies for DKD [7]. This evidence concerns the gene NR3C2 and diabetic kidney disease.